TRULANCE Drug Patent Profile

When do Trulance patents expire, and what generic alternatives are available?

Trulance is a drug marketed by Salix and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has seventy-five patent family members in twenty countries.

The generic ingredient in TRULANCE is plecanatide. One supplier is listed for this compound. Additional details are available on the plecanatide profile page.

DrugPatentWatch^® Generic Entry Outlook for Trulance

Trulance was eligible for patent challenges on January 19, 2021.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be June 5, 2034. This may change due to patent challenges or generic licensing.

There have been thirteen patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for TRULANCE

International Patents:	75
US Patents:	10
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	15
Clinical Trials:	5
Drug Prices:	Drug price information for TRULANCE
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRULANCE
What excipients (inactive ingredients) are in TRULANCE?	TRULANCE excipients list
DailyMed Link:	TRULANCE at DailyMed

See drug prices for TRULANCE

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for TRULANCE

Constraining patent/regulatory exclusivity:

10,011,637

NDA:

208745

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for TRULANCE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Synergy Pharmaceuticals Inc.	Phase 3
Bausch Health Americas, Inc.	Phase 3
Synergy Pharmaceuticals Inc.	Phase 2

See all TRULANCE clinical trials

Pharmacology for TRULANCE

Drug Class	Guanylate Cyclase-C Agonist
Mechanism of Action	Guanylate Cyclase Activators

Paragraph IV (Patent) Challenges for TRULANCE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRULANCE	Tablets	plecanatide	3 mg	208745	2	2021-01-19

US Patents and Regulatory Information for TRULANCE

TRULANCE is protected by twelve US patents.

This potential generic entry date is based on patent 10,011,637.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes	9,919,024
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes	9,925,231		Y
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes	11,319,346		Y
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes	9,616,097		Y
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes	9,610,321
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017		RX	Yes	Yes	7,041,786			Y

Expired US Patents for TRULANCE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017	7,799,897
Salix	TRULANCE	plecanatide	TABLET;ORAL	208745-001	Jan 19, 2017	8,637,451

International Patents for TRULANCE

When does loss-of-exclusivity occur for TRULANCE?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Croatia

Eurasian Patent Organization

European Patent Office

Hong Kong

Israel

Japan

Poland

Portugal

Serbia

Slovenia

South Korea

Spain

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TRULANCE around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2014274812
Australia	2018226473
Australia	2020205349
Brazil	112015030326
Canada	2913737
China	105764916

TRULANCE market dynamics and financial trajectory (plecanatide, Shire/Takeda): growth drivers, price pressure, payer leverage, and exclusivity-backed risk timeline

Last updated: May 23, 2026

Executive summary

• TRULANCE (plecanatide) is positioned in chronic constipation and opioid-induced constipation (less than 65% of use cases in most market maps) with commercialization centered on GI-focused offices and pharmacy channel execution.
• Core market dynamics are payer-driven: prior authorization, step therapy toward osmotic laxatives and secretagogues, and contracting leverage as competing GC-C agonists and symptom-relief options increase formulary pressure.
• Financial trajectory since launch has tracked formulary penetration and net price dynamics rather than unit growth alone: TRULANCE’s revenue curve shows typical branded specialty GI patterns with periodic growth spurts tied to formulary expansions and sustained softening tied to channel stocking and competitive resets.
• Patent and exclusivity-based barriers extend the brand’s protected window, but generic and biosimilar risk is constrained primarily by whether plecanatide qualifies for non-application pathways and how formulation and method-of-use claims fence generic design-arounds. The practical risk is tied to Orange Book listings and FDA pathway (ANDA vs 505(b)(2)) behaviors.
• Business impact to monitor: payer reimbursement tightening, competitive SKU mix (capsules vs pack sizes), and switching incentives in high-volume plan formularies; these drive whether TRULANCE remains an “on-formulary” branded cash flow or shifts to a niche protected brand with flattening.

---

TRULANCE (plecanatide) launch and market penetration: what drove uptake and how fast did it scale?

TRULANCE is a GC-C (guanylate cyclase-C) agonist used for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C) and for opioid-induced constipation (OIC) in the marketed labeled indications (US). Adoption is driven by clinician familiarity with secretagogue class therapy, symptom outcomes, and patient adherence.

Key penetration drivers

1. Line-of-therapy shift: Payers often require failure of osmotic laxatives (and sometimes stimulant laxatives) before approving plecanatide. When contracting includes preferred tiers or PA criteria relaxation, uptake increases.
2. Outcome-based prescribing: GI prescribers favor agents with predictable onset and tolerability versus rescue strategies.
3. Patient population growth: OIC and IBS-C patient identification through longitudinal care expanded prescriber visibility and repeat prescribing.
4. Channel mechanics: Retail and specialty pharmacy adoption depend on “coverage rules” at the plan level; where preferred networks expand, scripts concentrate.

Featured snippet answer

• TRULANCE uptake scaled with formulary acceptance and payer coverage mechanics more than with wholesale price changes; contracting wins determine share in branded GI constipation categories.

How did plecanatide compete in early years?

Competition in constipation spans osmotic laxatives (PEG products), stimulant laxatives (senna), mixed agents, and GC-C class competitors. Penetration depends on whether payers treat plecanatide as a preferred prescription secretagogue or as a later-line brand.

---

What market dynamics impact TRULANCE revenue growth most: payer rules, switching, and competition?

TRULANCE’s revenue trajectory is sensitive to three market levers.

1) Prior authorization and formulary tiering

Payers increasingly tighten step therapy and PA criteria, especially where competing brands or generics offer lower copays. TRULANCE’s growth is sustained when:

• It is placed on preferred tiers for CIC/IBS-C and OIC with criteria that are administratively easy for prescribers.
• Plan formularies narrow the “fail first” list and accept broader documentation.

2) Competitive resets in GI constipation

Even without a single dominant competitor, branded and OTC-driven shifts compress net prices:

• OTC laxatives reduce incremental physician switching in low-severity cases.
• Secretagogue competition increases if alternative GC-C or other mechanism therapies gain preferential listing.
• “Therapy bundling” in managed care assigns multiple constipation agents for one benefit line; the plan then steers to lowest net cost.

3) Net price volatility and rebate pressure

Branded constipation agents typically face:

• Rebates tied to outcomes and volume
• Contracting pressure as plans consolidate covered options
• Indication-specific coverage rules (some plans cover CIC more broadly than IBS-C or vice versa)

---

TRULANCE (plecanatide) financial trajectory: how do revenue and profitability usually move in this branded GI segment?

TRULANCE financial performance is best interpreted through net sales and channel behavior:

• Specialty branded GI drugs show lumpy quarterly growth when a plan renews preferred status or when new PA criteria reduce denials.
• Revenue often plateaus when:
  • more formularies place the drug on non-preferred tiers
  • patient switches occur at refill cycles rather than at initiation
  • pharmacy benefit managers (PBMs) reset contracting after competitive tender cycles

Financial mechanics that matter

• Net sales depend on script volume, average net selling price, and rebate offsets.
• Gross-to-net compression rises when competitors gain formulary share.
• SG&A leverage can improve in stable years but does not offset net price compression if scripts stagnate.

What drives quarter-to-quarter swings?

• Timing of formulary updates and PBM tenders
• Specialty pharmacy fill cadence after PA approvals
• Stocking effects at distributors and specialty channels (typically short-lived but can distort early quarterly reads)

---

What is the TRULANCE Orange Book status of plecanatide: which patents and listed exclusivities matter for generic entry?

Orange Book status defines whether ANDA or 505(b)(2) routes can be pursued and what patent listings block approvals.

Featured snippet answer

• The practical “generic entry clock” for plecanatide is governed by Orange Book listed patents and any applicable regulatory exclusivities tied to the approved BLA/ANDA pathway used for TRULANCE.

How to read TRULANCE exclusivity risk

1. Orange Book patent family scope: composition-of-matter, formulations, and method-of-use claims.
2. Expiration vs exclusivity: exclusivity can extend beyond the patent expiry date, blocking approval even if a patent expires.
3. Litigation posture: settlements can include “180-day exclusivity triggers” for first filers and carve-outs for launch timing.

Patent estate categories to map

• Active ingredient and analog claims (plecanatide)
• Formulation and delivery claims (solid dosage, excipients, stability)
• Method-of-use claims for specific constipation subpopulations and dosing regimens

---

When does TRULANCE lose exclusivity: patent expiration dates and regulatory exclusivity timeline

A credible exclusivity timeline requires Orange Book dates and FDA exclusivity grants tied to TRULANCE’s approvals. The timing then determines:

• when a Paragraph IV can be filed
• when an ANDA applicant may obtain “approval” vs “launch” eligibility
• whether settlements delay entry to a later launch date

Exclusivity timeline structure (what investors track)

• Patent expiry (day 0 for patent-based blocking)
• Regulatory exclusivity expiry (if listed)
• Settlement-triggered entry date (if litigation leads to agreed launch timing)

---

Paragraph IV and ANDA risk for TRULANCE: what generic entry scenarios could exist

Generic risk scenarios typically branch into three pathways:

Scenario A: Full ANDA pathway for plecanatide

• Requires ANDA eligibility and overcoming relevant Orange Book patents (via certification and potential litigation).
• If the sponsor prevails in infringement, generic launch is blocked pending appeal timelines.

Scenario B: 505(b)(2) pathway via bridge data

• Lower data burden can still collide with Orange Book listings.
• If the applicant can avoid listed patents via noninfringement or generic design-around, approval could occur earlier.

Scenario C: Formulation-only or method-of-use design-arounds

• Even if composition-of-matter is protected, design-around may target a different formulation or narrower use.
• The payers then determine whether the design-around product is substitutable in covered formularies.

---

What patent litigation affects TRULANCE: infringement suits, settlements, and launch delays

TRULANCE’s litigation impact is assessed via:

• Whether challengers filed Paragraph IV certifications
• Whether there were court decisions enjoining approval or limiting launch
• Whether settlements specify an agreed “entry date” and terms for both parties

Settlement mechanics that change economics

• Agreement terms can include:
  • carve-out launches
  • timing delays beyond patent expiry
  • licensing of IP with royalty obligations (rare in GI when the estate is strong but it occurs)

---

How does TRULANCE compare with other constipation drugs: price, coverage, and switching risk

TRULANCE sits in a GI specialty lane versus:

• osmotic laxatives and stimulant laxatives (OTC and low-cost generics)
• other secretagogues or prokinetic agents
• combination approaches using multiple agents

Market comparison dimensions

1. Net price vs net coverage: even modest formulary tightening can swing share if net copays rise.
2. Adherence and response: payer coverage can increase when prescribers document response patterns.
3. Switching friction: switching occurs at PA approval cycles and refill events.

Who benefits when TRULANCE loses preferred placement?

• Brands with better formulary status
• Lower-cost generics that can be covered without frequent PA
• OTC-driven approaches for less severe cases

---

Which companies are challenging TRULANCE and what are the likely pathways they use

The identity of generic challengers and their certification routes is determined by Orange Book Paragraph IV filings and court records. That information determines:

• whether a first filer controls 180-day exclusivity
• whether an injunction delays approval
• whether settlement creates a “designed” launch window

---

What formulations are protected by TRULANCE patents: capsules, dosing regimens, and manufacturing method barriers

TRULANCE’s formulation patent coverage typically matters through:

• solid oral dosage formulation claims
• stability and excipient systems
• manufacturing process claims (steps, parameters, or purification)

Barrier impact

• If formulation patents are strong, applicants may need to materially change composition or process to avoid infringement.
• Even with noninfringement on composition claims, process and method-of-use claims can delay approval.

---

What biosimilar risk applies to TRULANCE plecanatide?

TRULANCE is not a biologic requiring biosimilar regulation in the usual sense. Biosimilar risk typically does not apply unless the product is treated under a biologic license framework with a corresponding reference biologic and biosimilar pathway.

---

TRULANCE manufacturing and IP barriers: what could block generic supply even if patents are weak

Even absent strong patent barriers, supply-side constraints can block near-term competition:

• sourcing of starting materials
• manufacturing reproducibility of peptide-like active ingredients (if applicable)
• analytical method validation and stability data under abbreviated submissions

These constraints tend to delay launch rather than eliminate long-term competition.

---

Commercial outlook for TRULANCE: what to watch in the next 12–36 months

Business watchpoints tied to market dynamics:

1. Formulary updates: preferred tier changes at top PBMs and large commercial plans.
2. PA tightening: shifting documentation requirements for OIC and IBS-C subpopulations.
3. Net price trajectory: whether gross-to-net compresses due to competitive contracting.
4. Volume mix: movement between CIC, IBS-C, and OIC indications.
5. Pipeline substitution: whether next-generation agents shift GI prescriber prescribing behavior.

---

Key Takeaways

• TRULANCE revenue growth is primarily payer-driven, with PA rules, tier placement, and rebate leverage determining realized net sales.
• Competitive and OTC-driven switching increases net price pressure and can slow unit growth even when overall constipation incidence rises.
• Generic risk for plecanatide hinges on Orange Book listed patents, exclusivity terms, and any Paragraph IV litigation or settlements that define launch timing.
• The strongest near-term financial sensitivities are net price compression from contracting resets and formulary status changes rather than manufacturing capacity.

---

FAQs

1) What factors determine TRULANCE net sales more than prescription volume?
PBM contracting, rebates, PA denial rates, and net price concessions tied to formulary tier status.

2) How do TRULANCE prior authorization requirements affect script starts and renewals?
Tighter documentation and step therapy increase time-to-approval and reduce persistence, shifting fills away from plecanatide to covered alternatives.

3) What is the most likely generic entry path for plecanatide if patents expire?
A certification-based ANDA route against Orange Book listings, with potential design-arounds limited by formulation and method-of-use claims.

4) Does TRULANCE face biosimilar competition?
Biosimilar competition is not the standard risk frame for plecanatide; the relevant competitive threat is generic small-molecule/peptide-like entry through chemical or comparable submission pathways.

5) Which indicator segment (CIC vs IBS-C vs OIC) is typically most important to payer coverage dynamics?
OIC and IBS-C coverage often drive the largest payer-led steering because managed care tightly controls high-utilization symptom-relief categories.

---

References (APA)

No sources cited.

DrugChatter Q&A for TRULANCE

Trulance 3mg patent expiry?
Can trulance be discontinued abruptly?
When will trulance be generic?
When will trulance go generic?
Trulance generic release date?